Tumor necrosis factor-α inhibitor-induced follicular psoriasiform eruption

Tal Goldberger; Stephanie Benshushan; Zev Davidovics; Michael Wilschanski; Vered Molho-Pessach

doi:10.1111/pde.14993

Tumor necrosis factor-α inhibitor-induced follicular psoriasiform eruption

Pediatr Dermatol. 2022 Jul;39(4):598-600. doi: 10.1111/pde.14993. Epub 2022 Apr 24.

Authors

Tal Goldberger¹, Stephanie Benshushan², Zev Davidovics³, Michael Wilschanski³, Vered Molho-Pessach¹

Affiliations

¹ Department of Dermatology, The Faculty of Medicine, Hebrew University of Jerusalem, Hadassah Medical Center, Jerusalem, Israel.
² Department of Pathology, The Faculty of Medicine, Hebrew University of Jerusalem, Hadassah Medical Center, Jerusalem, Israel.
³ Department of Pediatric Gastroenterology, The Faculty of Medicine, Hebrew University of Jerusalem, Hadassah Medical Center, Jerusalem, Israel.

Abstract

Tumor necrosis factor-α inhibitor-associated adverse cutaneous reactions are common in patients with inflammatory bowel disease. Infection-related dermatoses and psoriasiform eruptions are seen most frequently. We describe a follicular psoriasiform eruption that appeared during treatment with infliximab in two adolescents with Crohn's disease.

Keywords: drug reaction; inflammatory disorders; psoriasis.

Publication types

Case Reports

MeSH terms

Adolescent
Antibodies, Monoclonal / adverse effects
Crohn Disease* / drug therapy
Exanthema* / chemically induced
Humans
Immunologic Factors / adverse effects
Infliximab / adverse effects
Psoriasis* / chemically induced
Psoriasis* / drug therapy
Psoriasis* / pathology
Skin Diseases, Infectious*
Tumor Necrosis Factor-alpha

Substances

Antibodies, Monoclonal
Immunologic Factors
Tumor Necrosis Factor-alpha
Infliximab